Antitumor-B KAC PK Study

Summary

Study Design: A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.

Timeline

Start

2026-12

Primary completion

2027-12

Completion

2027-12

Outcome

Outcome not reported

Stopped: “Study abandoned.”

Drugs

Indications